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A B S T R A C T   
Introduction of sentinel lymph node biopsy, initially in clinically node-negative and subsequently in patients 
presenting with involved axilla and downstaged by primary systemic therapy, allowed for significant decrease in 
morbidity compared to axillary lymph node dissection. Concurrently, regional nodal irradiation was demon-
strated to improve outcomes in most node-positive patients. Additionally, over the last decades, introduction of 
more effective systemic therapies has resulted in improvements not only at distant sites, but also in locoregional 
control, creating space for de-escalation of locoregional treatments. We discuss the data on de-escalation in 
axillary surgery and irradiation, both in patients undergoing upfront surgery and primary systemic therapy, with 
special emphasis on the feasibility of omission of nodal irradiation in patients undergoing primary systemic 
therapy. In view of the accumulating evidence, omission of axillary irradiation may be considered in clinically 
node-positive patients converting after primary systemic therapy to pathologically negative nodes on sentinel 
lymph node biopsy (preferably also with in-breast pCR), presenting with lower initial nodal stage, older age and 
were treated with breast-conserving surgery followed by whole breast irradiation. Omission of regional nodal 
irradiation in patients with aggressive tumor phenotypes achieving a pCR is under investigation. In patients 
undergoing preoperative endocrine therapy the adoption of axillary management strategies utilized in case of 
upfront surgery seems more suitable than those used in post chemotherapy-based primary systemic therapy 
setting.  
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Introduction 
Decades of progress in early breast cancer (BC) treatment, in 
particular advances in early detection and tumor-biology-driven sys-
temic therapy have resulted in improvements in both local/distant 
control and overall survival (OS) [1]. Resultant improved disease con-
trol together with the morbidity associated with locoregional treatments 
have led to locoregional treatment (surgery and radiation) de-escalation 
attempts, aiming to decrease treatment-related sequelae and – as a result 
– improve patients’ quality-of-life. 
In regional lymph node (LN) management the first steps were made 
in axillary surgery. Already at the turn of the centuries sentinel lymph 
node biopsy (SLNB) in clinically node-negative (cN0) patients with 
omission of axillary lymph node dissection (ALND) in sentinel lymph 
node (SLN)-negative patients became a standard of care [2]. Almost 
twenty years later, the American College of Surgeons Oncology Group 
(ACOSOG) Z0011 randomized trial demonstrated the feasibility of 
ALND omission in patients with limited axillary nodal involvement (<3 
positive nodes), treated with tangential breast irradiation and adjuvant 
systemic therapy (Table 1) [3]. 
Additionally, the randomized International Breast Cancer Study 
Group (IBCSG) 23–01 and AATRM 048/13/2000 trials and the single 
arm SENOMIC study confirmed the safety of ALND omission in patients 
with one or more micrometastatic (≤2 mm) SLN [4,5,9]. More recently 
the SINODAR One trial assessed the feasibility of ALND omission 
following SLNB in a relatively higher risk population with clinically T1- 
T2N0 tumors and 1–2 SLN macrometastases, irrespective of surgery to 
the primary tumor (breast-conserving surgery (BCS) vs mastectomy) [6]. 
At a median follow-up of 30 months, no axillary recurrences were 
observed. Of note, around 20% of patients in the SLNB arm underwent 
mastectomy, and the use of radiation therapy (RT) was left to treating 
physician’s discretion (no details were reported). Several ongoing trials 
addressing similar unmet needs are still ongoing (SENOMAC - 
NCT02240472, POSNOC - NCT02401685, INSEMA - NCT02466737) 
[10–12]. Finally, the AMAROS (European Organisation for Research and 
Treatment of Cancer (EORTC) 0981–22023) and OTOASOR trials 
confirmed comparable axillary control and a decrease in lymphoedema 
(AMAROS) in cT1–2 N0 SLN-positive patients treated with axillary RT, 
as compared with ALND [8,13]. 
Interestingly, the largely forgotten National Surgical Adjuvant Breast 
and Bowel Project (NSABP) B-04 trial conducted in the early 1970s, in 
patients having only clinical evaluation of preoperative nodal status and 
no adjuvant systemic treatments, demonstrated no significant difference 
at 25-year follow-up in terms of disease-free survival (DFS), relapse-free 
survival, distant-disease-free survival, or OS in cN0 patients who have 
been randomly assigned to conventional radical mastectomy, total 
mastectomy with postoperative regional nodal irradiation (RNI) or total 
mastectomy followed by ALND at axillary recurrence [14]. Similarly, 
there was no difference in outcomes between patients with clinically 
positive nodes (cN+) treated by radical mastectomy or by total mas-
tectomy and RT. However, all outcomes were dramatically worse 
compared to more recent findings, which makes the translation to cur-
rent practice impossible. 
Genomic profiling for locoregional treatment decisions 
Another approach to de-escalate axillary treatment is to select pa-
tients according to genomic profile. In the NSABP B-28 trial, which 
randomized node-positive patients to more versus less aggressive post-
operative chemotherapy (AC-T vs AC) and in which no RNI was allowed, 
a strong relationship between the Oncotype DX Breast Recurrence 
Score® (RS) and locoregional recurrence (LRR) risk was demonstrated, 
with 11.2 years risk of LRR of 3.3%. 7.2% and 12.2% for patients with 
low, intermediate and high scores, respectively [15]. Similarly, among 
the 316 estrogen receptor (ER)-positive, node-positive patients from the 
Southwest Oncology Group trial S8814, who underwent mastectomy 
without postmastectomy radiation therapy (PMRT) (252 patients) or 
breast-conserving therapy (BCT) including whole breast irradiation 
(WBI) (64 patients) followed by tamoxifen alone, chemotherapy fol-
lowed by tamoxifen, or concurrent tamoxifen and chemotherapy, esti-
mated 10-year cumulative LRR rates were 9.7% for low and 16.5% for 
intermediate or high RS (p = .02) [16]. This difference remained sig-
nificant among postmastectomy patients, with 10-year actuarial LRR 
rates of 7.7% for low vs 16.8% for intermediate or high RS (p = .03). 
Importantly, in a subset of postmastectomy patients with 1–3 involved 
nodes, the low RS group had only 1.5% LRR rate, suggesting a possibility 
of omitting RT. It is important to remember, though, that these patients 
routinely underwent ALND. 
The ongoing NCIC MA.39 trial is assessing the role of RNI in ER- 
positive, low genomic risk (RS <18) patients with 1–3 involved LN, 
treated with modern systemic therapies (NCT03488693) [17]. However, 
as the trial includes patients both after SLNB and ALND, the feasibility of 
Table 1 
Published/presented trials on de-escalation of axillary surgery in patients undergoing de novo surgery.  
Trial Patient number SLN involvement Breast 
surgery 






891 (target accrual 
1900) 
≤2 SLN, without gross 




tangential fields obligatory, 51%* “high tangents”, 
19%* “on purpose” third regional nodal irradiation 
field; irrespective of SLNB or ALND arm 
10 SLNB 80,2% 
ALND 78,2% 
IBCSG 23-01  
[4] 
934 (target accrual 
1960) 
micrometastases only 90% BCT 97% of BCT patients had RT (19% intraoperative 
only) 




247 (target accrual 
352) 
micrometastases only 92% BCT RT (breast only) in all BCT patients; high tangents 
or axillary field not allowed 
5 SLNB/ALND 
98,2% 
Sinodar One  
[6] 
889 (target accrual 
2000) 
1–2 macrometastases 78% BCT RT indication independent of the omission of 
ALDN, no details reported 




AMAROS [7] 4823 (1425 
randomized) 
60% macrometastases, 29% 
micrometastases, 11% ITC 
82% BCT no ALND arm: 4 levels of the axilla 10 SLNB + RT 
78,2% (DMFS) 
SLNB + ALND 
81,7% (DMFS) 
OTOASOR [8] 2106 (526 
randomized, 474 
analyzed) 
60% macrometastases, 36% 
micrometastases, 6% ITC 
84% BCT no ALND arm: 4 levels of the axilla 8 SLNB + RT 
77,4% 
SLNB + ALND 
72,1% 
ALND – axillary lymph node dissection, BCT – breast conserving therapy, ITC – isolated tumor cells, RT – radiation therapy, SLN – sentinel lymph node 
* applies to patients with known RT field details (calculations extrapolated among patients with known and unknown tangent height). 
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axillary de-escalation in the SLNB subgroup may be difficult to 
demonstrate. 
Role of axillary radiation therapy in patients undergoing 
upfront surgery 
A number of RT trials and population registry series have demon-
strated the benefit of RNI (Table 2). 
In the Canadian MA.20 trial the addition of RNI (including internal 
mammary, supraclavicular, and axillary LN) in 1832 women with node- 
positive or high-risk node-negative BC treated with BCS and adjuvant 
systemic therapy resulted in 10-year DFS improvement (82.0% for RNI 
vs 77.0% for the control; HR 0.76; 95 %CI 0.61–0.94; p = .01), albeit 
without OS difference [18]. The EORTC 22922/10925 “Internal mam-
mary” trial, which randomized 4004 patients with involved axillary 
nodes and/or a medially located primary to irradiate or not the internal 
mammary and medial supraclavicular LN, at a median FU of 15.7 years 
showed significant reduction of BC mortality (HR 0.81; 95 %CI 
0.69–0.94; p = .005) and BC recurrence (HR 0.87; 95 %CI 0.77–0.98; p 
= .024), also without OS improvement (HR 0.95; 95 %CI 0.84–1.06; p =
.358) [19]. A smaller French trial randomized 1407 patients with posi-
tive axillary nodes or central/medial tumors to receive postoperative 
chest wall and supraclavicular nodes irradiation with or without internal 
mammary nodes (IMN). The study failed to demonstrate a statistically 
significant survival benefit, although a numerical, potentially clinically 
meaningful >3% difference in 10-year OS in favor of IMN irradiation 
was observed and the negative interpretation of this trial may have 
resulted from insufficient sample size [20]. Additionally, in a series of 
3089 patients from the Danish Breast Cancer Cooperative Group (DBCG) 
registry managed by a uniform policy of IMN irradiation only in patients 
with right-sided tumors, a reduction in BC mortality (adjusted HR 0.85; 
95 %CI 0.73–0.98; p = .03) and OS improvement in favor of IMN irra-
diation (adjusted HR 0.82; 95 %CI, 0.72–0.94; p = .005) without 
increased risk of death from ischemic heart disease was observed [21]. 
However, the role of irradiation of particular nodal sub-volumes cannot 
be evaluated based on the outcomes of these studies because of the 
differences in target volumes. It is also important to remember that all 
the “old” trials demonstrating BC mortality benefit from PMRT involved 
RNI [22]. However, taking into account the consistent improvements in 
locoregional control, resulting from modern systemic therapies, these 
results might not be fully applicable to currently treated patients 
[23–25]. 
Importantly, the Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) meta-analysis evaluating 13,404 patients in 14 RNI trials 
found no effect on BC recurrence or BC mortality and increased non–BC 
related mortality leading to increased overall mortality in 8 studies 
starting between 1961 and 1978. In sharp contrast, RNI significantly 
reduced BC recurrence, BC mortality and any death, without increased 
non-BC related mortality in six studies initiated after 1989 [24]. 
The ACOSOG Z0011 trial demonstrated that ALND may be safely 
omitted in in patients with limited axillary nodal involvement treated 
with tangential field irradiation and adjuvant systemic therapy [3]. 
However, the trial protocol did not specify the details of postoperative 
RT. In an analysis of the ACOSOG Z0011 radiation field design, 18.9% of 
patients received directed RNI using ≥3 fields and among >80% pa-
tients irradiated with tangential beams only, approximately 50% were 
treated with so-called “high tangents” (cranial border ≤2 cm from hu-
meral head), leaving only approximately 40% treated with “classical” 
tangential beams technique [26]. 
According to a study comparing dose coverage of regional LN areas 
following the Z0011, AMAROS, EORTC 10981–22023 and MA-20 field 
design, high tangent irradiation resulted in a similar dose distribution in 
levels I and II of the axilla, as compared to the field design in the 
AMAROS trial, which included intentional axillary irradiation [27]. It 
also needs to be remembered that both ACOSOG Z0011 and IBCSG 
23–01 enrolled relatively low-risk node-positive patients. ACOSOG 
Z0011 allowed for inclusion of patients with ≤2 positive SLN, without 
gross extranodal disease and no primary systemic therapy (PST). >70% 
of patients in the SLNB arm had only one involved SLN and in 45% only 
micrometastatic disease was present [3]. An even lower risk population 
was enrolled in the IBCSG 23–01 study, which allowed for only micro-
metastatic disease and no PST. In this study 95% had involvement of 
only one SLN and approximately 90% of patients underwent BCT, 
including breast irradiation [4]. Importantly, although tangential-field 
WBI does not assure reliable dose coverage of levels I and II of the ax-
illa, therapeutic irradiation dose is delivered to at least part of this 
volume in a significant percentage of patients [28–30]. 
More supportive data on omission of axillary LN irradiation comes 
from a prospective series from the Memorial Sloan Kettering Cancer 
Center (MSKCC – New York, United States), validating the ACOSOG 
Z0011 results in real-world setting [31]. Among the 484 patients treated 
with SLNB alone with a minimum follow-up of 12 months, 103 cases 
received WBI using a prone technique (which practically excludes 
axillary irradiation) and only one nodal relapse (1%) was observed [31]. 
De-escalation of axillary treatment in patients undergoing pri-
mary systemic therapy 
Surgical trials have demonstrated that in patients without clinical 
nodal involvement at baseline sensitivity and long-term outcomes of 
SLNB performed after PST are identical to those undergoing upfront 
surgery [32,33]. However, nodal involvement was a classical indication 
for ALND before the era of PST. Yet, PST allows for conversion from 
limited nodal involvement (cN1) to negative nodal status (ypN0) in 
approximately 40% of patients [34]. Trials attempting to define the role 
of SLNB in patients presenting with nodal involvement and treated with 
modern PST have demonstrated satisfactory sensitivity in the post-PST 
setting, provided dual tracer is used or at least 3 SLN are identified 
(Table 3) [34–39]. 
However, because all patients in these studies underwent ALND, long 
term outcomes including the axillary recurrences after SLNB alone are 
unknown. Such information was provided by a prospective MSKCC 
cohort of cN1 patients receiving PST followed by a negative SLNB and no 
further axillary surgery [40]. Among the 610 patients included, 234 
Table 2 





Irradiated LN groups 
(difference between arms) 
DFS OS Comment 
MA.20 [18] 1832 9.5 years IM, SC, AX ↑ (82.0% vs 77.0%, HR 
0.76; p = .01) 
NS RT to operated axilla in case of <10 LN 
examined or >3 LN involved 
EORTC 22922/ 
10925 [19] 
4004 15.7 years IM, medial SC NS NS RT to operated axilla only if inadequate 
surgery 
DMFS NS, ↓ BC recurrence and BC 
mortality 
French [20] 1334 11.3 years IM NS NS  
DBCG [21] 3089 8.9 years IM – ↑ (75.9% vs 72.2%, HR 
0.82, p = .005) 
DMFS NS, ↓ BC mortality 
AX – axilla, BC – breast cancer, DMFS – distant metastasis-free survival, HR – hazard ratio, IM – internal mammary, LN – lymph nodes, NS – not significant, RT – 
radiation therapy, SC – supraclavicular. 
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(42%) had ≥3 negative SLNs and underwent SLNB alone. Of those, 205 
(88%) received postoperative RT, with 164 (80%) receiving RNI. At a 
median follow-up of 35 months, there was only 1 (0.4%) axillary 
recurrence, synchronous with a breast recurrence, in a patient who 
refused RT. In another series of 688 consecutive cT1-3 cN0-2 patients 
operated at the European Institute of Oncology (Milan, Italy) 
(2000–2015), who became or remained cN0 after PST and underwent 
SLNB with at least one SLN found, ALND was not performed even if a 
single SLN was negative and nodal RT was not mandatory [41]. Despite 
less strict axillary management, including RNI only in 10.9% of cN+ BCT 
patients and 37.9% of cN+ postmastectomy patients, after 9.2-year 
median follow-up axillary failures occurred in only 1.8% of initially 
cN1-2 and in 1.5% of initially cN0 patients. 
The LRR risk in PST treated patients is related to intrinsic tumor 
phenotype. In the ACOSOG Z1071 the highest LRR risk was observed 
among triple-negative tumors (HR 5.91 comparing to hormone- 
receptor-positive BC) [42]. In the EORTC 10,994 (p53) trial the high-
est rate of LRR as first event was seen among HER2-positive tumors 
treated without trastuzumab (10.4%) and triple-negative tumors (8.9%) 
[43]. However, this phenomenon seems to be balanced by a good 
response to PST. In the series of 751 patients treated with PST and BCT at 
MD Anderson Cancer Center (Houston, United States), 5-year LRR-free 
survival rate in patients with 4 main phenotypes (ER+/HER2-, ER+/ 
HER2+, ER-/HER2-, ER-/HER2+ ), who achieved pathological com-
plete response (pCR) ranged from 97.4% to 100% [44]. Among similarly 
treated group of 335 patients from a single Korean institution, after 
median 7.2 years follow-up, there were no LRRs among triple-negative 
patients, who achieved a pCR [45]. Similar, 100% 5-year locoregional 
control in the pCR subgroup was observed among 233 patients treated 
with PST, mastectomy and postoperative RT at MSKCC [46]. Addition-
ally, in the National Cancer Database (NCDB) series of triple-negative 
and HER2-positive cN+ patients, who achieved a breast pCR, the rate 
of node positivity at surgery was as low as 1.6% [47]. Based on these 
data, EUBREAST initiated a trial evaluating omission of SLNB in triple- 
negative and HER2-positive BC patients with in-breast pCR after PST 
(NCT04101851). 
In patients with residual axillary nodal involvement ALND remains 
standard, as even in micrometastatic disease LRR seems high even in 
patients achieving breast pCR [48]. Indeed, among the 1617 patients 
from the NCDB (2006–2014) and matched for patient, tumor, and 
treatment characteristics, SLNB (+ RNI) was associated with signifi-
cantly lower survival, compared to ALND (+ RNI) (HR 1.7, 95 %CI 
1.3–2.2, p < .001), with estimated 5-year OS of 71% and 77%, respec-
tively [49]. Exploratory subgroup analyses showed that SLNB was 
comparable with ALND in patients with luminal A or B tumors with 
single metastatic LN (HR 1.03, 95 %CI 0.59–1.8, p = .91). However, in 
another, more recent NCDB series (2012–2015) of 1411 cT1-3 N1 ypN1 
patients, OS of these treated with SLNB with RNI (206 patients) and 
ALND + RNI (1205 patients) did not differ (5-year OS: 76% vs. 73%, p =
.39; after propensity score matching: 79% vs. 69%, p = .33, respectively) 
[50]. 
Another approach towards de-escalation of axillary treatment, 
although with limited application outside The Netherlands due to reg-
ulatory issues, includes the combined use of PET/CT before PST and the 
MARI (removal of axillary LN marked with radioactive iodine seeds) 
procedure after PST [51]. According to this protocol, patients showing 
1–3 FDG-avid axillary LN (cN <4) and a tumor-negative MARI node 
(MARI-) receive no further axillary treatment. All cN <4 patients with a 
tumor-positive MARI node (MARI+), as well as patients with ≥4 FDG- 
avid LNs [cN(4+)] and MARI- receive locoregional RT. An ALND is 
performed only for cN(4+) patients with MARI+. After 16 months of 
follow-up no LRR were seen in 39 patients (24.5%) in whom no RNI was 
used and only 1 - among 71 patients (44.7%) in whom ALND was 
replaced by RNI, in spite of residual axillary disease at surgery. 
The 2021 the St. Gallen Consensus Guidelines support the recom-
mendation for ALND in case of residual nodal macrometastases after 
PST. RNI may be a potentially acceptable alternative to ALND in patients 
with micrometastatic disease or isolated tumor cells. Importantly, sys-
temic treatment options such as capecitabine or trastuzumab emtansine 
for residual invasive cancer are not considered equivalent alternatives to 
ALND [52]. 
Radiation management of axilla after PST is less straightforward. As 
far, as there is general agreement on no need of RNI in cN0 patients 
remaining pathologically node-negative (ypN0) after PST and on 
avoidance of axillary irradiation in the post-ALND setting. However, the 
role of axillary irradiation in patients who convert from cN+ to ypN0 
after PST and are spared ALND is much less clear, and many guidelines 
urge caution concerning RT tailored by response to PST [53,54]. Also, 
the recently published policy review on local management following 
PST for early BC does not provide much guidance on the details of RNI 
[55]. 
High-level evidence data from prospective, optimally randomized 
studies on the role of axillary irradiation in this patient subgroup are 
lacking. In this framework, recommendations have to be made from less 
direct evidence. The pooled analysis of NSABP B-18 and NSABP B-27 
trials provided prospective data on locoregional control in a homoge-
nous population of PST-treated patients [56]. Both trials strictly defined 
the locoregional management: lumpectomy patients received breast RT 
alone; mastectomy patients were not allowed RT. Axillary surgery 
routinely employed ALND. Independent predictors of LRR in lumpec-
tomy patients were age, baseline clinical nodal status, and pathologic 
breast tumor and nodal status; in mastectomy patients, these were 
baseline clinical tumor size and nodal status, and pathologic nodal sta-
tus/breast tumor response (Fig. 1). 10-year LRR probability in mastec-
tomy patients remained <10%, irrespective of primary tumor size in 
pCR patients and in clinically (pre-PST) and pathologically node- 
negative patients, who failed to achieve in-breast pCR. In the lumpec-
tomy + WBI group the LRR risk was strongly age-related and the only 
subgroup which LRR risk remained <10% for all age groups were cN0 
patients, who achieved a pCR; slightly worse outcomes were seen in 
clinically and pathologically node-negative patients, who failed to 
achieve pCR in the breast and in cN+ patients who achieved a pCR. The 
highest LRR risk in both subgroups was observed among pathologically 
node-positive patients (HR 2.71). Interestingly, relatively lower nodal 
recurrence risk was observed among BCT, as compared to mastectomy 
patients, despite numerically higher recurrence rate in the ipsilateral 
breast. One of the possible explanations could be that in the BCT sub-
group at least part of the nodal areas received therapeutic irradiation 
doses from the tangential fields. 
Finally, in the unpublished CTNeoBC metanalysis, LRR rates in 
postmastectomy patients were lower in the subgroup with (3.8%) vs. 
Table 3 
Published trials on de-escalation of axillary surgery in cN+ patients converting 





False negative rate 
ACOSOG Z1071 
[35] 
689 92.7% 12.6% (9.1% in patients 
with >2 SLN identified, 
10.8% with dual tracer) 
SENTINA [36] 592 (Arm 
C) 
80.1% 14.2% (4.9% in patients 
with >2 SLN identified, 
8.6% with dual tracer) 
SN FNAC [37] 153 87.6% 8.4% (4.9% in patients 
with >2 SLN identified, 
5.2% with dual tracer) 
GANEA 2 [38] 307 79.5% 11.9% 
Swedish [39] 195 77.9% (80.7% 
with dual tracer) 
14.1% (4% in patients with 




150 93% 16.1% 
SLN – sentinel lymph node. 
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without (8.1%) pCR, irrespective of RT use, whereas in lumpectomy 
patients, LRR rates were similar in patients with (6.0%) and without 
(6.3%) pCR [57]. Interestingly, in hormone receptor–positive, HER2- 
negative patients with a pCR low recurrence rates, regardless of grade 
and type of breast surgery, were observed. Among ypN+ patients, grade 
3 tumors were associated with significantly higher LRR rate than grade 1 
or 2 cancers, suggesting a place for omission of RT in the latter group. 
[57]. Unfortunately, information on the use and details of postoperative 
RT was lacking. 
Indirect information on postoperative RT efficacy in post-PST pa-
tients may be derived from population-based registries such as NCDB, 
post hoc analyses of clinical trials or retrospective patient series (Table 4) 
[58]. 
Among 10,283 cT1-3 N1 postmastectomy patients from NCDB 
(2003–2011), 3040 (29.6%) converted to ypN0. The use of post-
operative RT was associated with improved OS independently of nodal 
response (ypN+, HR 0.795; p < .001 and ypN0, HR 0.743; p = 0.19) 
[59]. However, in another NCDB (1998–2009) series of 1560 post-
mastectomy, stage II (node-positive) or III patients who converted to 
ypN0, no OS benefit was observed from postoperative RT. Although the 
RT group patients had more advanced disease, PMRT showed no asso-
ciation with OS on multivariate analysis [60]. Significant improvement 
was seen, however, in higher-risk subgroups, such as clinical stage IIIB/ 
IIIC disease (p = .027), T3/T4 tumors (p = 0.25) or residual invasive 
disease after PST (p = .041). In a series of 16,535 postmastectomy pa-
tients (2010–2015) improvement in adjusted OS with the use of PMRT 
was seen among ypN1, but not ypN0 patients [61]. In another NCDB 
series (2004–2008) of 8321 cN1-2 patients who underwent PST followed 
by mastectomy and were unselected for pathological nodal status, PMRT 
was associated with an OS benefit in both cN1 (5-year OS 75.8% vs. 
71.9%, p < .01) and cN2 (5-year OS 69.2% vs. 58.6%, p < .01) sub-
groups [62]. In the subgroup of ypN0 patients, PMRT improved OS for 
hormone-receptor negative patients but not hormone-receptor positive 
patients. 
In a combined analysis of three German Breast Group trials (Gepar-
Trio, GeparQuattro, GeparQuinto), in 817 postmastectomy, non- 
inflammatory BC patients, among whom RT was administered to 676 
(82.7%), in the multivariate analysis RT was associated with borderline 
lower risk of LRR (HR 0.51, 95 %CI 0.27–1.0; p = .05). This effect was 
mostly expressed in cT3/4 and cN+ patients, including those who con-
verted to ypN0 [63]. Additional risk factors for LRR included lack of ER 
and progesterone receptor, and baseline nodal status. In the ACOSOG 
Z1071 trial, where patients treated with mastectomy and ALND under-
went RT at physician’s discretion, omission of PMRT was associated 
with higher LRR risk (HR 4.84; 95 %CI 1.50–15.61; p = .008) [42]. 
Further subset analysis demonstrated that the RT omission detriment 
was limited to patients with residual node-positive disease (HR 4.14; 95 
%CI 1.15–14.92; p = .030). This detrimental effect on LRR did not, 
however, translate into other long-term outcomes, such as DFS, BCSS or 
OS. In another series of 185 cT1-3 N1 BC patients, who converted to 
Fig. 1. 10-year risk of locoregional recurrence for breast conserving therapy 
(A) and mastectomy (B) following preoperative chemotherapy in pooled anal-
ysis of NSABP B-18 and NSABP B-27 trials [56]. cN – clinical nodal status 
(before preoperative chemotherapy), pCR – pathological complete response, 
XRT – radiation therapy; ypN – pathologic nodal status (after preoperative 
chemotherapy). 
Table 4 
Effect of radiation therapy in cN+ patients converting to ypN0 after primary 
systemic therapy.   




Effect of postoperative RT 








1560 OS NS 
↑ OS in clinical stage IIIB/ 








1937 OS NS 
↑ OS in HR- patients 
Gepar Trials [63] 158 borderline ↓ LRR 
ACOSOG Z1071  
[35] 
157 LRR, DFS, BCSS, OS NS 
Chinese [64] 185 ↓ LRR, ↓ DM, ↑ DFS, OS NS 
KROG 12–05 [65] 151 LRR, DFS, OS NS 
Institut Curie [66] 92 LRR, DFS, OS NS 
MD Anderson  
[67] 
106 Stage I and II LRR – NS, 







2070 OS NS 
ACOSOG Z1071  
[35] 




4842 OS NS 
Centre René 
Huguenin [68] 
84 DFS, OS NS 
KROG 12–05 [65] 251 LRR, DFS, OS NS 
BSC – breast conserving surgery, BCSS – breast cancer-specific survival, DFS – 
disease-free survival, DM – distant metastases, HR – hormone-receptor, LRR – 
locoregional recurrence, NS – non-significant, OS – overall survival, pCR – 
pathological complete response, RNI – regional nodal irradiation. 
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ypN0, treated in a single Chinese institution (Beijing, China) between 
1999 and 2013, for patients with and without PMRT, the 5-year LRR, 
distant metastasis, DFS and OS rates were 1.1% and 7.5% (p = .071), 
5.1% and 15.0% (p = 0.023), 95.0% and 79.0% (p = 0.008), and 100.0% 
and 94.5% (p = 0.089), respectively [64]. In patients with stage III 
disease, the 5-year LRR and DFS rates were 1.9% and 14.4% (p = 0.041) 
and 91.9% and 67.4% (p = 0.022), respectively, whereas in stage II 
patients the 5-year distant metastasis and DFS rates were 0 and 11.5% 
(p = 0.044), and 100.0% and 84.9% (p = 0.023), respectively. In 
contrast, in a similar multicenter retrospective study from Korea (KROG 
12–05) the 5-year DFS, LRRFS, and OS rates, although numerically in 
favor of PMRT (91.2, 98.1, 93.3% with PMRT vs 83.0%, 92.3%, and 
89.9% without PMRT), weren’t statistically different [65]. No effect 
from PMRT on LRR, DFS and OS was also seen in a series from Institut 
Curie (Paris, France) [66]. In a series of 226 patients from MD Anderson, 
who achieved a pCR, no benefit from PMRT was seen for stage I and II 
patients, however, the 10-year LRR rate was significantly improved with 
PMRT for Stage III patients (7.3% for PMRT vs. 33.3% without PMRT; p 
= .040) [67]. 
In a systematic review on the use of PMRT in post-PST patients 
clinical stage II (T1-2 N0-1), age >40 years, estrogen receptor-positivity, 
pCR or 0–3 positive nodes without lymphovascular invasion or extrac-
apsular extension, were identified as associated with ≤10% risk of LRR 
without radiation [69]. No detailed information on the PMRT benefit 
was provided, however, in relation to the pathological nodal status. 
In BCT patients, among 5032 cT1-3 N1 undergoing PST (NCDB 
2003–2011), no benefit from the addition of RNI to WBI was seen, both 
in ypN0 and ypN+ patients [59]. Also, in the ACOSOG Z1071, the BCT 
subgroup of the KROG 12–05 and among 9474 patients from another 
NCDB series (2010–2015), no benefit from RNI was observed, irre-
spective of pathological nodal status [42,61,70]. In a series of 248 ypN0 
patients from Centre René Huguenin (Saint-Cloud, France) no difference 
in DFS and OS in relation to the RNI use was seen both among cN0 (164 
patients) and cN+ (84 patients) subgroups [68]. In another Korean study 
(KROG 16–06) of 261 ypN0 patients (41% cN+), ALND was found to be 
the only favorable factor for locoregional control and RNI had no effect 
on LRR, DFS, or OS, irrespective of the response to PST [71]. The lack of 
RNI benefit in BCT patients may be explained that in many of these trials 
and series the routinely used tangential breast irradiation often involved 
also a large part of the axilla. 
Finally, a recent systematic review attempting to assess the role of 
RNI in cN2 patients converting to ypN0, based on 4 retrospective studies 
of 1107 patients (3 studies – postmastectomy, 1 study – BCT) demon-
strated numerical, although not statistically different improvements in 
DFS (91.2% vs 83%) and LRR-free survival (98.1% vs 92.3%) from 
locoregional RT [72]. Additionally, loco-regional RT was associated 
with an OS benefit among patients with stage IIIB-C (79.3% vs 71.2%, p 
= .027) and T3-T4 tumors (82.6% vs 76.6%, p = .025). 
The current major guidelines in most cases strongly recommend RNI 
(with avoidance of operated axilla) for both clinical and pathological 
(yp) nodal involvement [53,54]. The only exception was the 2019 St. 
Gallen Consensus, in which RNI in case of cN1 patients converting to 
ypN0 was recommended only in the presence of additional adverse 
factors [73]. This, however, is being changed back in the 2021 edition to 
a strong recommendation against omitting RNI for patients whose pre-
sented with a clinically positive axillary node(s), even when pCR is 
achieved [52]. 
More light on the feasibility of axillary de-escalation will be shed by 
ongoing phase III randomized trials in baseline cN+ patients undergoing 
PST followed by surgery including SLNB. The NSABP B-51/RTOG 1304 
randomizes cT1-3pN1 patients who converted to ypN0 into RNI vs no 
RNI (NCT01872975) [74]. In the higher risk ypN+ population the 
ALLIANCE A011202 trial is evaluating omission of completion ALND in 
patients undergoing RNI (NCT01901094) [75]. The main objective of 
the SAKK 23–16/IBCSG 57–18/ABCSG-53/GBG 101 (TAXIS) trial is to 
test the hypothesis that in mixed population of cN+ patients undergoing 
PST or upfront surgery including tailored axillary surgery, axillary RT in 
pathologically node-positive patients is non-inferior to ALND in terms of 
DFS (NCT03513614) [76]. The feasibility of omission of ALND and RNI 
in patients with micrometastatic SLN will be assessed by the NEONOD2 
trial (NCT040196780) [77]. Additionally, a Dutch Prospective Regis-
tration Study (RAPCHEM/BOOG 2010–03) (NCT01279304) evaluated 
the outcome of risk-adapted irradiation policy based on the ypN status: 
(1) ypN0 (low-risk): WBI and no PMRT; (2) ypN1 (intermediate-risk): RT 
to breast or chest wall, in case of no ALND: RT to level I and II of the 
axilla; (3) ypN2 (high-risk): RT to breast or chest wall and regional LN 
(excluding operated axilla) [78]. The assessment of the chosen policy in 
this study may, however, be hampered by many deviations from the RT 
protocol observed, especially in intermediate-risk patients. 
In view of the accumulating evidence, omission of axillary RT in 
cN+, post-PST patients undergoing SLNB may be considered in patients 
with ypN0 (preferably also with in-breast pCR), lower initial N stage, 
older age and treated with BCS followed by WBI. RNI may probably also 
be omitted in patients with aggressive tumor phenotypes achieving a 
pCR (Table 5). 
A practice of selecting patients for RNI based on ypN status after PST 
is, however, already existing, as demonstrated among 26,009 patients 
from the NCDB (2010–2015) [61]. Over the observed time-period, the 
use of RNI among ypN1 patients increased from 49% to 59%, whereas it 
remained stable at approximately 44% among ypN0 patients. 
Finally, it should be stressed, that axillary RT, if indicated, should 
routinely be applied only to the unoperated part of the axilla, given that 
most failures occur in the unoperated part of the nodal drainage area and 
that adding RT to surgery increases lymphoedema rates [18,19]. 
Axillary de-escalation after primary (neoadjuvant) endocrine 
therapy (PS(E)T) 
Chemotherapy-based PST in ER-positive, HER2-negative patients is 
related to lowest pCR rates among all BC phenotypes [79]. Also, the 
nodal pCR rate in this subgroup remains the lowest [80]. The pCR rates 
after PS(E)T are even lower, differing from 4.1 to <10% after PS(E)T vs. 
15.6% after chemotherapy [81,82]. 
No standards exist regarding axillary management following residual 
disease after PS(E)T and it is often assumed that it should mirror that 
after chemotherapy-based PST. As the probability of conversion of cN+
to ypN0 after PS(E)T is very low, the recommendations applying to 
situation after chemotherapy-based PST may not be applicable here. 
Additionally, it needs to be remembered that patients undergoing sur-
gery after chemotherapy-based PST have in most cases already 
completed all planned treatment of this particular modality (i.e., no 
further improvement in outcome from this treatment can be expected), 
whereas in case of PS(E)T the patients usually have finished only few 
months out of 5–10 years of endocrine treatment planned and the 
pathological status at surgery does not reflect the efficacy of fully 
completed treatment. Furthermore, patients with gross nodal involve-
ment are likely to additionally receive adjuvant chemotherapy. 
Unfortunately, none of the PS(E)T trials have evaluated the type and 
outcomes of axillary management. A hypothesis generated by the group 
from Dana Farber/Brigham and Women’s Cancer Center (Boston, United 
States), that minimal residual nodal burden after PS(E)T would not have 
a detrimental impact on long-term outcomes, because patients selected 
for PS(E)T have not received their full systemic therapy at the time of 
surgery resulted in a comparative analysis of patients undergoing 
upfront vs post-PS(E)T surgery in relation to pathological nodal status 
[83]. In a series of 3406 PS(E)T-treated patients, matched in a pro-
pensity score analysis for clinical characteristics of age, race, clinical 
tumor and nodal stage, histology, grade, type of surgery, and presence of 
lymphovascular invasion with same number of patients undergoing 
upfront surgery, 5-year OS between patients from both cohorts was 
similar for all analyzed nodal stages. Another analysis from the same 
group demonstrated that in the NCDB cohort of PS(E)T patients there 
was no difference in 5-year estimated OS by type of axillary surgery 
(SLNB vs ALND) in any residual nodal disease burden subgroup (ypN0; 
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1–2 positive nodes; ≥3 positive nodes) [84]. It needs to be remembered, 
however, that due to pattern of relapse of luminal tumors characterized 
by late recurrences, 5-year OS may be not the optimal end point. 
Thus, as survival outcomes for PS(E)T patients are more resembling 
patients undergoing upfront surgery rather than patients treated with 
chemotherapy-based PST and the prognostic significance of residual 
nodal disease after PS(E)T mirrors that after upfront surgery, in this 
patient population the adoption of axillary management strategies uti-
lized in case of upfront surgery may be more appropriate than those used 
in post chemotherapy-based PST setting. 
Conclusions 
One of the goals in treating BC patients should be to tailor the tri- 
modality treatment according to the risk of recurrence, this will allow 
to reduce morbidity associated with therapy and costs without 
compromising outcomes. Decreasing the intensity of regional manage-
ment of the axilla started with trials of SLNB in patients undergoing 
upfront surgery and significantly progressed with the wide diffusion of 
PST. Conversion of cN+ disease into ypN0 allows for reduction in the 
extent of axillary dissection, and – in some cases – probably also in the 
use and extent of postoperative RT. It needs to be remembered, however, 
that, as reported by the EBCTCG metanalysis, the introduction of PST 
initially resulted in increased LRR rates, most probably resulting from 
reducing extent of locoregional treatments following disease down-
staging [85]. Another pitfall of available data suggesting possible further 
de-escalation of axillary management is that most come from retro-
spective analyses, which are statistically underpowered and no final 
conclusions can be made before results from ongoing prospective ran-
domized trials become available. Another possible approach towards 
therapeutic de-escalation while maintaining very low LRR rates in pa-
tients at low risk of distant relapses, is the reduction of systemic therapy 
utilization combined with optimal locoregional control by RT. 
Extreme caution should be taken, however, when deciding about 
omission of particular therapeutic components. We encourage strongly 
to conduct this de-escalation process in a stepwise manner, carefully 
monitoring for increased LRR rates. This should be accompanied by 
collecting relevant patient-, tumor- and treatment-related data to allow 
for fully informed evaluation of treatment de-escalation outcomes. For 
this, enrollment of patients preferably into prospective controlled ran-
domized studies or, if not feasible, into high-quality registries is of 
utmost importance. 
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